Our Approach

our approach

Our advisory work starts from a position of respect
for our clients' organization, people,
products and science.

OUR RELATIONSHIPS

our approach

We have devoted our careers to the life
sciences industry and have the deepest respect
and admiration for the participants in it.

OUR TRACK RECORD

our approach

We are a very active advisor in the market.
Torreya Partners has successfully closed over
100 assignments since our founding in 2007.

Our Perspective

our approach

We often take an operating perspective
to strategic and transaction work.

Hikma Pharmaceuticals

Sale of ANDAs

February 2016

North America

H2-Pharma

Sale to ANI Pharmaceuticals

$10 million

February 2016

North America

PhosImmune

Sale to Agenus

$10 million upfront in cash & stock + up to $3

December 2015

North America

May 10-11, 2016

BioEquity Europe

Copenhagen, Denmark

May 31-June 1, 2016

Boston CEO Conference

Boston, MA

June 3-7, 2016

ASCO – Annual Meeting

Chicago, IL

February 29, 2016

Hikma Announces the Close of the Roxane Laboratories Acquisition

MORE

February 1, 2016

ANI Pharmaceuticals Acquires Exclusive Rights to Distribute Three Generic Drug Products from H2-Pharma for $10 Million

MORE

December 23, 2015

Agenus Acquires PhosImmune with a Novel Class of Cancer Neoantigens

MORE